Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Allergy Immunotherapy Market

ID: MRFR/HC/54532-HCR
200 Pages
Nidhi Mandole
April 2026

China Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) andBy Patient Type (Pediatric, Adult, Geriatric)- Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Allergy Immunotherapy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

China Allergy Immunotherapy Market Summary

As per MRFR analysis, the China Allergy Immunotherapy Market was estimated at 169.8 USD Million in 2024. The allergy immunotherapy industry is projected to grow from 185.82 USD Million in 2025 to 457.62 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 9.43 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The China Allergy Immunotherapy Market is experiencing robust growth driven by increasing allergy prevalence and supportive government initiatives.

  • The largest segment in the market is sublingual immunotherapy, which is gaining traction due to its convenience and efficacy.
  • The fastest-growing segment is injectable immunotherapy, reflecting advancements in treatment techniques and patient acceptance.
  • Rising awareness of allergy treatments and increased investment in healthcare infrastructure are propelling market expansion.
  • The supportive regulatory environment and rising incidence of allergic conditions are key drivers influencing market dynamics.

Market Size & Forecast

2024 Market Size 169.8 (USD Million)
2035 Market Size 457.62 (USD Million)
CAGR (2025 - 2035) 9.43%

Major Players

Boehringer Ingelheim (DE), Allergopharma (DE), Merck KGaA (DE), Stallergenes Greer (GB), Aimmune Therapeutics (US), DBV Technologies (FR), Novartis (CH), Sanofi (FR), Bristol-Myers Squibb (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

China Allergy Immunotherapy Market Trends

The China Allergy Immunotherapy Market is currently experiencing a notable transformation, driven by increasing awareness of allergic conditions and the efficacy of immunotherapy treatments. The prevalence of allergies in the population has prompted healthcare providers to explore innovative solutions, leading to a rise in demand for immunotherapy options. This shift is further supported by government initiatives aimed at enhancing healthcare access and promoting advanced treatment modalities. As a result, the market is witnessing a gradual expansion, with a growing number of patients seeking personalized treatment plans tailored to their specific allergic responses. Moreover, advancements in research and technology are playing a pivotal role in shaping the landscape of the China Allergy Immunotherapy Market. The development of novel allergen extracts and the integration of digital health solutions are enhancing patient engagement and treatment adherence. Additionally, collaborations between pharmaceutical companies and healthcare institutions are fostering a more robust ecosystem for allergy management. This collaborative approach not only improves treatment outcomes but also encourages the establishment of standardized protocols for immunotherapy administration. Overall, the market appears poised for continued growth, driven by a combination of patient-centric innovations and supportive regulatory frameworks.

Rising Prevalence of Allergies

The increasing incidence of allergic conditions among the Chinese population is a key driver for the China Allergy Immunotherapy Market. As more individuals are diagnosed with allergies, the demand for effective treatment options, particularly immunotherapy, is likely to rise. This trend suggests a growing recognition of the importance of addressing allergic disorders through specialized therapies.

Government Support and Regulation

Government initiatives aimed at improving healthcare access and promoting advanced treatment options are influencing the China Allergy Immunotherapy Market. Regulatory bodies are likely to implement policies that facilitate the development and approval of immunotherapy products, thereby enhancing the market's growth potential. This supportive environment may encourage innovation and investment in allergy treatments.

Technological Advancements in Treatment

Innovations in research and technology are shaping the future of the China Allergy Immunotherapy Market. The introduction of new allergen extracts and digital health solutions is enhancing patient engagement and treatment adherence. These advancements may lead to more personalized and effective immunotherapy options, ultimately improving patient outcomes in allergy management.

China Allergy Immunotherapy Market Drivers

Supportive Regulatory Environment

The supportive regulatory environment in China plays a crucial role in fostering the growth of the China Allergy Immunotherapy Market. The government has implemented policies aimed at promoting the development and approval of new immunotherapy products. In 2025, the National Medical Products Administration streamlined the approval process for allergy treatments, reducing the time required for new therapies to reach the market. This regulatory support encourages pharmaceutical companies to invest in research and development, leading to a wider array of treatment options for patients. As the regulatory landscape continues to evolve favorably, it is anticipated that the market will experience accelerated growth.

Rising Awareness of Allergy Treatments

The growing awareness regarding allergy treatments among the Chinese population is a notable driver for the China Allergy Immunotherapy Market. As more individuals become informed about the benefits of immunotherapy, there is an increasing demand for these treatments. Public health campaigns and educational initiatives have contributed to this awareness, leading to a rise in patient inquiries and consultations. In 2025, it was estimated that approximately 30 million people in China were seeking allergy treatments, indicating a substantial market potential. This heightened awareness is likely to propel the growth of the immunotherapy sector, as patients actively seek effective solutions for their allergy-related issues.

Rising Incidence of Allergic Conditions

The increasing incidence of allergic conditions in China is a critical driver for the China Allergy Immunotherapy Market. Reports indicate that the prevalence of allergic rhinitis and asthma has been on the rise, affecting millions of individuals across the country. In 2025, it was estimated that around 20% of the Chinese population suffered from some form of allergy, creating a substantial demand for effective treatment options. This trend is likely to continue, as urbanization and environmental factors contribute to the worsening of allergic conditions. Consequently, the growing patient population seeking immunotherapy is expected to drive the market forward.

Advancements in Immunotherapy Techniques

Technological advancements in immunotherapy techniques are significantly influencing the China Allergy Immunotherapy Market. Innovations such as sublingual immunotherapy and monoclonal antibodies have emerged, providing patients with more effective and convenient treatment options. In 2025, the introduction of new immunotherapy products led to a 15% increase in market growth compared to the previous year. These advancements not only enhance treatment efficacy but also improve patient compliance, as newer methods often involve less frequent dosing. As research and development continue to progress, the market is likely to witness further innovations that will attract more patients to seek immunotherapy.

Increased Investment in Healthcare Infrastructure

The Chinese government has been investing heavily in healthcare infrastructure, which is a significant driver for the China Allergy Immunotherapy Market. Enhanced healthcare facilities and the establishment of specialized allergy clinics have made immunotherapy more accessible to patients. In 2025, the healthcare expenditure in China reached over 6 trillion yuan, with a portion allocated specifically for allergy treatments. This investment not only improves the quality of care but also encourages the development of new immunotherapy products. As healthcare infrastructure continues to expand, it is expected that more patients will have access to allergy immunotherapy, thereby stimulating market growth.

Market Segment Insights

By Application: Allergic Rhinitis (Largest) vs. Allergic Asthma (Fastest-Growing)

In the China Allergy Immunotherapy Market, the application segments exhibit distinct characteristics in terms of market share. Allergic Rhinitis leads as the largest segment, driven by its high prevalence among the population. In contrast, Allergic Asthma and Atopic Dermatitis are also significant but take a relatively smaller share, while Food Allergies continue to maintain a stable presence, potentially showing gradual growth in awareness and diagnosis. The distribution reflects the varying degrees of awareness and treatment options available for these conditions in the region. Growth trends within this segment indicate a promising trajectory for Allergic Asthma, which is recognized as the fastest-growing segment due to increasing pollution levels and lifestyle changes triggering respiratory issues. There is also a growing focus on personalized immunotherapy treatments, alongside robust awareness campaigns that are helping to drive the increase in market participation for these conditions. Such trends highlight the adaptive nature of the immunotherapy market in response to changing health needs and consumer awareness.

Allergic Rhinitis (Dominant) vs. Atopic Dermatitis (Emerging)

The characteristics of Allergic Rhinitis position it as the dominant segment within the China Allergy Immunotherapy Market, attributed to its widespread occurrence among individuals, especially in urban areas with higher pollution levels. Treatment approaches for Allergic Rhinitis have become conventional and include various immunotherapy options, making it a staple in allergy management. Meanwhile, Atopic Dermatitis is emerging as a segment gaining traction, characterized by increased research and development investments, targeting consumer education, and the introduction of novel treatment options. With rising cases of skin allergies, Atopic Dermatitis is witnessing enhanced focus from both healthcare providers and pharmaceutical companies, indicating a shift towards broader immunotherapy applications in the future.

By Type of Immunotherapy: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing)

The China Allergy Immunotherapy Market displays a diverse array of treatment options, with Subcutaneous Immunotherapy leading the market as the largest segment. This method, which involves the administration of allergen extracts through injections, has garnered significant acceptance due to its long history and proven efficacy. Following closely is Sublingual Immunotherapy, which has been rapidly gaining traction among patients seeking a more convenient and less invasive alternative. Its ease of administration contributes to a growing population of patients opting for this method. In recent years, there has been a notable shift towards Sublingual Immunotherapy as it offers a favorable safety profile and the convenience of self-administration, driving its growth in the market. Increased awareness about allergic disorders and the efficacy of immunotherapy has led to more individuals seeking treatment. Furthermore, supportive regulatory frameworks and advancements in formulation techniques are expected to foster the growth of both Subcutaneous and Sublingual approaches, shaping the future landscape of allergy treatment in China.

Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging)

Subcutaneous Immunotherapy remains the dominant player in the China Allergy Immunotherapy Market due to its established effectiveness and comprehensive clinical validation over the years. Patients typically receive a series of injections that gradually increase the dosage of allergens, which helps build immunity over time. This method is particularly suited for individuals with severe allergies and provides long-lasting results. However, the rising popularity of Sublingual Immunotherapy as an emerging option signals a shift in patient preference, particularly among those looking for less invasive treatment alternatives. Sublingual therapy, which allows patients to place allergen tablets or drops under their tongue, is perceived as more user-friendly and is leading to increased patient adherence. As healthcare providers continue to recognize its benefits, Sublingual Immunotherapy is likely to expand its foothold in the market.

By Patient Demographics: Children (Largest) vs. Adults (Fastest-Growing)

In the China Allergy Immunotherapy Market, patient demographics play a crucial role in market dynamics. Children represent the largest segment, largely driven by the increasing prevalence of allergic conditions among this age group. As awareness about allergy management grows among parents, there has been a significant rise in immunotherapy adoption for pediatric patients, leading them to command a substantial share of the market. Meanwhile, adults emerge as the fastest-growing segment, attributed to lifestyle changes, environmental factors, and rising incidences of adult-onset allergies, which have elevated the demand for effective treatment options in this demographic. The growth trends in this segment reflect broader societal changes, including increased urbanization and pollution levels in China, prompting more adults to seek relief from allergy symptoms through immunotherapy. Recent studies indicate improvements in awareness and acceptance of allergy treatments, further fueling this growth. Moreover, the expansion of access to healthcare and evolving treatment protocols are catering to the needs of both segments, thereby enhancing overall market progression. This trend is expected to continue as more targeted therapies and patient education initiatives unfold over the coming years.

Children: Dominant vs. Adults: Emerging

The segment of children remains dominant in the China Allergy Immunotherapy Market, primarily due to their heightened vulnerability to allergies, which have markedly increased in prevalence over recent years. Children, particularly those exposed to environmental allergens, are often the prime targets for early intervention through immunotherapy, as parents seek proactive treatments to alleviate severe allergic reactions. On the other hand, the adult segment is emerging strongly, driven by lifestyle changes and an increase in awareness of adult allergies. Adults increasingly recognize the impact of allergies on their quality of life, prompting a shift towards innovative immunotherapy solutions. The distinct characteristics of both demographics highlight a dual focus for providers, emphasizing preventive measures for children and tailored approaches for adults to meet their unique treatment needs.

By Treatment Duration: Long-term (Largest) vs. Maintenance Therapy (Fastest-Growing)

In the China Allergy Immunotherapy Market, the treatment duration segment is characterized by a diverse array of options, prominently featuring Long-term therapy, which captures the largest market share. Short-term and Induction therapy segments also contribute significantly, but their market positions are comparatively lower. Maintenance Therapy is gaining traction as patients seek ongoing relief, establishing itself as a notable contender within this segment. Growth trends within the treatment duration segment are influenced by increasing awareness of allergy immunotherapy benefits and the need for sustained treatment options. As healthcare providers emphasize the importance of long-term management of allergic conditions, Long-term therapy remains dominant. However, Maintenance Therapy is emerging as the fastest-growing segment, driven by patient adherence and the convenience of continuous care as a preferred option for managing allergies.

Long-term (Dominant) vs. Maintenance Therapy (Emerging)

Long-term therapy represents the dominant approach within the China Allergy Immunotherapy Market, characterized by its ability to provide sustained relief from allergy symptoms through prolonged treatment. This method is often favored for its effectiveness in achieving lasting desensitization. In contrast, Maintenance Therapy has emerged as a vital alternative, appealing to patients seeking ongoing care with minimal disruption to their daily lives. It allows for personalized treatment plans that ensure continuous management of allergic reactions. This shift towards Maintenance Therapy indicates a growing trend where patients prefer sustained approaches accompanied by regular check-ups and adjustments based on their individual responses, reflecting a broader demand for flexible and patient-centered care strategies.

Get more detailed insights about China Allergy Immunotherapy Market
Request Free Sample

Key Players and Competitive Insights

The China Allergy Immunotherapy Market is currently characterized by a dynamic competitive landscape, driven by increasing prevalence of allergic conditions and a growing awareness of immunotherapy as a viable treatment option. Key players such as Boehringer Ingelheim (DE), Merck KGaA (DE), and Aimmune Therapeutics (US) are strategically positioning themselves through innovation and regional expansion. Boehringer Ingelheim (DE) has focused on enhancing its product portfolio with novel therapies, while Merck KGaA (DE) emphasizes partnerships to bolster its research capabilities. Aimmune Therapeutics (US) is actively pursuing collaborations to expedite the development of its peanut allergy treatment, thereby shaping a competitive environment that prioritizes innovation and strategic alliances.

In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The market appears moderately fragmented, with several players vying for market share. This fragmentation is influenced by the diverse needs of patients and healthcare providers, which necessitates tailored solutions. The collective influence of key players is significant, as they drive advancements in treatment options and patient access, thereby enhancing the overall market structure.

In January 2026, Aimmune Therapeutics (US) announced a strategic partnership with a leading Chinese pharmaceutical company to enhance the distribution of its peanut allergy immunotherapy. This collaboration is expected to facilitate faster market entry and improve accessibility for patients in China, reflecting Aimmune's commitment to addressing local needs. The strategic importance of this partnership lies in its potential to significantly increase Aimmune's market presence and drive revenue growth in a rapidly evolving landscape.

In December 2025, Merck KGaA (DE) launched a new digital platform aimed at educating healthcare professionals about the benefits of immunotherapy. This initiative underscores the company's focus on digital transformation and its recognition of the need for enhanced education in the market. By leveraging technology, Merck KGaA (DE) aims to improve treatment adoption rates and foster stronger relationships with healthcare providers, which could lead to increased market penetration.

In November 2025, Boehringer Ingelheim (DE) expanded its research and development facilities in China, signaling a long-term commitment to the region. This expansion is likely to enhance the company's ability to innovate and respond to local market demands. The strategic importance of this move lies in its potential to accelerate the development of new therapies tailored to the unique needs of Chinese patients, thereby strengthening Boehringer's competitive position.

As of February 2026, current trends in the China Allergy Immunotherapy Market indicate a shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on technology and supply chain reliability rather than solely on price. This shift suggests that companies that prioritize innovation and adaptability will likely emerge as leaders in the market.

Key Companies in the China Allergy Immunotherapy Market include

Industry Developments

The China Allergy Immunotherapy Market has seen significant developments recently, characterized by advancements in both technology and regulatory approvals. Notable companies such as Jiangsu Hengrui Medicine and Sinopharm Group are intensifying their Research and Development efforts in personalized allergy treatments, aiming to enhance efficacy and patient compliance. In July 2023, BeiGene announced a collaboration with Hua Medicine to develop innovative immunotherapies that target specific allergens, reflecting the growing trend of partnerships to accelerate product pipelines in this sector.Moreover, the market is witnessing increased investments, with Wuhan Fuxing Science and Technology reporting a substantial growth in valuation due to an influx of funding for their allergen immunotherapy devices. Merger and acquisition activities have also been prominent; in August 2023, Shenzhen Salubris Pharmaceuticals completed the acquisition of Guangzhou Baiyunshan Pharmaceutical Holdings, which is expected to strengthen its portfolio in the allergy treatment domain. This consolidation is indicative of a broader trend aimed at enhancing market presence and expanding therapeutic offerings. Over the past two years, innovation in formulations and an emphasis on regulatory compliance have further driven competitiveness among market players, paving the way for growth in China's allergy immunotherapy landscape.

Future Outlook

China Allergy Immunotherapy Market Future Outlook

The China Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2024 to 2035, driven by increasing allergy prevalence, technological advancements, and rising healthcare expenditure.

New opportunities lie in:

  • Development of personalized immunotherapy solutions for specific allergens.
  • Expansion of telehealth platforms for remote allergy consultations.
  • Investment in AI-driven diagnostics for allergy identification and treatment optimization.

By 2035, the market is expected to be robust, reflecting substantial growth and innovation.

Market Segmentation

China Allergy Immunotherapy Market Application Outlook

  • Allergic Rhinitis
  • Allergic Asthma
  • Atopic Dermatitis
  • Food Allergies

China Allergy Immunotherapy Market Treatment Duration Outlook

  • Short-term
  • Long-term
  • Maintenance Therapy
  • Induction Therapy

China Allergy Immunotherapy Market Patient Demographics Outlook

  • Children
  • Adults
  • Elderly
  • Gender Specific

China Allergy Immunotherapy Market Type of Immunotherapy Outlook

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy
  • Oral Immunotherapy
  • Intranasal Immunotherapy

Report Scope

Report Scope:
Report Attribute/Metric Source: Details
MARKET SIZE 2018 319.2(USD Million)
MARKET SIZE 2024 342.6(USD Million)
MARKET SIZE 2035 750.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.383% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
MARKET FORECAST PERIOD 2025 - 2035
HISTORICAL DATA 2019 - 2024
MARKET FORECAST UNITS USD Million
KEY COMPANIES PROFILED Happymeds, Sinopharm Group, Jiangsu Hengrui Medicine, Hua Medicine, BeiGene, Sino Biopharmaceutical, Wuhan Fuxing Science and Technology, Guangzhou Baiyunshan Pharmaceutical Holdings, Huangming Pharmaceutical, Shenzhen Salubris Pharmaceuticals
SEGMENTS COVERED Type, Product, Indication, Patient Type
KEY MARKET OPPORTUNITIES Increasing prevalence of allergies, Growing investment in R&D, Expanding patient awareness programs, Advancements in personalized therapies, Rising demand for effective treatments
KEY MARKET DYNAMICS increasing allergy prevalence, government support for research, growing patient awareness, advancements in treatment options, competitive market landscape
COUNTRIES COVERED China
Author
Author
Author Profile
Nidhi Mandole LinkedIn
Senior Research Analyst
She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get In Touch
Leave a Comment

FAQs

What is the current valuation of the China Allergy Immunotherapy Market?

<p>The market valuation was 169.8 USD Million in 2024.</p>

What is the projected market size for the China Allergy Immunotherapy Market by 2035?

<p>The projected valuation for 2035 is 457.62 USD Million.</p>

What is the expected CAGR for the China Allergy Immunotherapy Market during the forecast period?

<p>The expected CAGR for the market from 2025 to 2035 is 9.43%.</p>

Which segments are included in the China Allergy Immunotherapy Market?

<p>The market segments include Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies.</p>

What are the key types of immunotherapy in the market?

<p>Key types of immunotherapy include Subcutaneous, Sublingual, Oral, and Intranasal Immunotherapy.</p>

How does the market perform across different patient demographics?

<p>The market performance varies, with Adults projected to generate 70.0 to 200.0 USD Million.</p>

What is the revenue range for Allergic Rhinitis in the market?

<p>The revenue range for Allergic Rhinitis is between 50.0 and 130.0 USD Million.</p>

Which companies are leading the China Allergy Immunotherapy Market?

<p>Key players include Boehringer Ingelheim, Merck KGaA, and Novartis.</p>

What is the revenue range for Sublingual Immunotherapy?

<p>Sublingual Immunotherapy is projected to generate between 40.0 and 120.0 USD Million.</p>

What are the expected revenue ranges for long-term treatment in the market?

<p>Long-term treatment is expected to generate between 51.84 and 138.12 USD Million.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓
%>